Claims for Patent: 9,421,194

Summary for Patent: 9,421,194

Title:	Lung targeting dual drug delivery system
Abstract:	The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.
Inventor(s):	Prud\'homme; Robert K. (Lawrenceville, NJ), Sinko; Patrick J. (Annandale, NJ), Stone; Howard A. (Princeton, NJ), Pinkerton; Nathalie M. (Ottawa Hills, OH), Shi; Lei (Shanghai, CN), Wan; Jiandi (Lawrenceville, NJ), Ibrahim; Sherif (Old Bridge, NJ), Gao; Dayuan (East Brunswick, NJ)
Assignee:	Rutgers, The State University of New Jersey (New Brunswick, NJ) The Trustees of Princeton University (Princeton, NJ)
Application Number:	13/080,371
Patent Claims:	1. A delivery system comprising a gel microparticle, a plurality of nanoparticles associated with the gel microparticle, and one or more hydrophobic drugs associated with at least one of the nanoparticles, wherein the gel microparticle includes aqueous soluble polymers or copolymers that are gelled by a crosslinking reaction selected from the group consisting of free radical polymerization, mannich reactions, hydrophobic association, metal ion mediated complexation, amide formation reactions, ester formation reactions, and azide alkyne Huisgen cycloaddition, and the nanoparticles include PEG protective coatings. 2. The delivery system of claim 1 further comprising at least one of one or more targeting agents associated with at least one of the nanoparticles or one or more chemopotentiator associated with at least one of the nanoparticles. 3. The delivery system of claim 1, wherein the gel microparticles include polymers and degradable linkages between individual ones of the polymers. 4. The delivery system of claim 1, wherein the gel microparticles have a size of 1-60 .mu.m. 5. The delivery system of claim 1, wherein the gel microparticles have a size selected from the group consisting of 6-10 .mu.m and 50-60 .mu.m. 6. The delivery system of claim 1, wherein the shear modulus of the gel microparticle is from 4 Pa to 200,000 Pa. 7. The delivery system of claim 1, wherein the gel microparticle includes gelled polymers or copolymers selected from at least one of poly(2-hydroxyethyl methacrylate), polyphosphate, polyethylene glycol, PEG, or copolymers thereof, dextran, polyvinyl pyrrolidone or co-polymers thereof, or polyacrylic acid or copolymers thereof. 8. The delivery system of claim 1, wherein the gel microparticle includes gelled polymers or copolymers selected from at least one of polyethylene glycol, PEG, having a molecular weight from 200 to 200,000 g/mole, dextran having a molecular weight from 200 to 100,000 g/mole, polyvinyl pyrrolidone or copolymers thereof having a molecular weight from 200 to 100,000 g/mole, or polylactic acid-polyethylene glycol-polylactic acid, PLA-PEG-PLA, polymers. 9. The delivery system claim 1, wherein the one or more hydrophobic drugs includes a substance selected from the group consisting of an asthma therapeutic agent, a chronic obstructive pulmonary disease therapeutic agent, a tuberculosis therapeutic agent, a cancer therapeutic agent, a non-small cell lung cancer therapeutic agent, signal transduction inhibitors, cytotoxic agents, cell cycle inhibitors, cell cycle control inhibitors, checkpoint inhibitors that interfere with the normal function of cell cycle checkpoints, checkpoint inhibitors that interfere with the normal function of cell cycle S/G2 checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G2/M checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G1/S checkpoint, topoisomerase inhibitors, camptothecins, enzymes necessary for DNA replication, enzymes necessary for DNA transcription, receptor tyrosine kinase inhibitors, apoptosis inducing agents, antimetabolites, gemcitabine, hydroxyurea, telomerase inhibitors, cyclin-dependent kinase inhibitors, cytoskeletal proteins, transcription factors, tumor suppresser genes, DNA damaging agents, DNA repair inhibitors, anti-angiogenic agents, mitochondrial poisons, carboplatin, cisplatin, cyclophosphamide, doxorubicin, daunorubicin, epirubicin, mitomycin C, mitoxantrone, 5-fluorouracil (5-FU), FUDR, methotrexate, topoisomerase I inhibitors, irinotecan, topotecan, S/G2 checkpoint inhibitors, bleomycin, docetaxel, etoposide, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine, genistein, trastuzumab, ZD1839, apoptosis-inducing agents, a TB therapeutic agent, ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, aminoglycosides, amikacin (AMK), kanamycin (KM), polypeptides, capreomycin, viomycin, enviomycin, fluoroquinolones, ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF), thioamides, ethionamide, prothionamide, cycloserine, p-aminosalicylic acid (PAS or P), rifabutin, macrolides, clarithromycin (CLR), linezolid (LZD), thioacetazone (T), thioridazine, arginine, vitamin D, R207910, SQ641, a COPD therapeutic agent, short-acting selective beta.sub.2-adrenoceptor agonists, adrenergic agonists, anticholinergic medications and long-acting .beta..sub.2-agonists, or a pharmaceutically acceptable salt of one of the foregoing. 10. The delivery system of claim 1 further comprising a pharmaceutically acceptable carrier. 11. A method of treating a condition comprising administering a delivery system to a patient in need thereof, the delivery system including a gel microparticle, a plurality of nanoparticles associated with the gel microparticle, and one or more hydrophobic drugs associated with at least one of the nanoparticles, wherein the gel microparticle includes aqueous soluble polymers or copolymers that are gelled by a crosslinking reaction selected from the group consisting of free radical polymerization, mannich reactions, hydrophobic association, metal ion mediated complexation, amide formation reactions, ester formation reactions, and azide alkyne Huisgen cycloaddition, and the nanoparticles include PEG protective coatings. 12. The method of claim 11, wherein the step of administering includes intravenous injection. 13. The method of claim 11, wherein the step of administering includes intra-arterial injection. 14. The method of claim 11, wherein the delivery system further includes at least one of one or more targeting agents associated with the nanoparticles or one or more chemopotentiators associated with the nanoparticles. 15. The method of claim 11, wherein the gel microparticles include polymers and degradable linkages between individual ones of the polymers. 16. The method of claim 11, wherein the gel microparticles have a size of 1-60 .mu.m. 17. The method of claim 11, wherein the gel microparticles have a size selected from the group consisting of 6-10 .mu.m and 50-60 .mu.m. 18. The method of claim 11, wherein the one or more hydrophobic drugs includes a substance selected from the group consisting of an asthma therapeutic agent, a chronic obstructive pulmonary disease therapeutic agent, a tuberculosis therapeutic agent, a cancer therapeutic agent, a non-small cell lung cancer therapeutic agent, signal transduction inhibitors, cytotoxic agents, cell cycle inhibitors, cell cycle control inhibitors, checkpoint inhibitors that interfere with the normal function of cell cycle checkpoints, checkpoint inhibitors that interfere with the normal function of cell cycle S/G2 checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G2/M checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G1/S checkpoint, topoisomerase inhibitors, camptothecins, enzymes necessary for DNA replication, enzymes necessary for DNA transcription, receptor tyrosine kinase inhibitors, apoptosis inducing agents, antimetabolites, gemcitabine, hydroxyurea, telomerase inhibitors, cyclin-dependent kinase inhibitors, cytoskeletal proteins, transcription factors, tumor suppresser genes, DNA damaging agents, DNA repair inhibitors, anti-angiogenic agents, mitochondrial poisons, carboplatin, cisplatin, cyclophosphamide, doxorubicin, daunorubicin, epirubicin, mitomycin C, mitoxantrone, 5-fluorouracil (5-FU), FUDR, methotrexate, topoisomerase I inhibitors, irinotecan, topotecan, S/G2 checkpoint inhibitors, G2/M checkpoint inhibitors, bleomycin, docetaxel, etoposide, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine, G1/early-S checkpoint inhibitors, genistein, trastuzumab, ZD1839, apoptosis-inducing agents, a TB therapeutic agent, ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, aminoglycosides, amikacin (AMK), kanamycin (KM), polypeptides, capreomycin, viomycin, enviomycin, fluoroquinolones, ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF), thioamides, ethionamide, prothionamide, cycloserine, p-aminosalicylic acid (PAS or P), rifabutin, macrolides, clarithromycin (CLR), linezolid (LZD), thioacetazone (T), thioridazine, arginine, vitamin D, R207910, SQ641, a COPD therapeutic agent, short-acting, selective beta.sub.2-adrenoceptor agonists, adrenergic agonists, anticholinergic medications and long-acting .beta..sub.2-agonists, or a pharmaceutically acceptable salt of one of the foregoing. 19. The method of claim 11, wherein the delivery system further includes a pharmaceutically acceptable carrier. 20. The delivery system of claim 1, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from camptothecin, gemcitabine, carboplatin, cisplatin, doxorubicin, daunorubicin, topotecan, bleomycin, docetaxel, or paclitaxel. 21. The delivery system of claim 1, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from ethambutol, isoniazid, pyrazinamide, rifampicin, or streptomycin. 22. The delivery system of claim 1, wherein the one or more hydrophobic drugs include camptothecin. 23. The delivery system of claim 1, wherein the one or more hydrophobic drugs include rifampicin. 24. The delivery system of claim 1, wherein the aqueous soluble polymers or copolymers include PEG polymers having a molecular weight of 200 to 200,000 g/mole. 25. The delivery system of claim 1, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more hydrophobic drugs include camptothecin. 26. The delivery system of claim 1, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more drugs include rifampicin. 27. The method of claim 11, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from camptothecin, gemcitabine, carboplatin, cisplatin, doxorubicin, daunorubicin, topotecan, bleomycin, docetaxel, or paclitaxel. 28. The method of claim 11, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from ethambutol, isoniazid, pyrazinamide, rifampicin, or streptomycin. 29. The method of claim 11, wherein the one or more hydrophobic drugs include camptothecin. 30. The method of claim 11, wherein the one or more hydrophobic drugs include rifampicin. 31. The method of claim 11, wherein the aqueous soluble polymers or copolymers include PEG polymers having a molecular weight of 200 to 200,000 g/mole. 32. The method of claim 11, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more hydrophobic drugs include camptothecin. 33. The method of claim 11, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more hydrophobic drugs include rifampicin.

Details for Patent 9,421,194

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-04-05
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-04-05
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2030-04-05